NDASUBCUTANEOUSSOLUTION
Approved
Jan 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
9
Data completeness
6/8 — Strong
ZEMBRACE SYMTOUCH (sumatriptan succinate) by Antares Therapeutics is 5-ht 1b/1d receptors. First approved in 2016.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEMBRACE SYMTOUCH is a subcutaneous solution of sumatriptan succinate approved in 2016 for acute migraine treatment. It works as a 5-HT 1B/1D receptor agonist, causing cranial vessel constriction and inhibiting pro-inflammatory neuropeptide release in the trigeminal system. This autoinjector formulation offers rapid symptom relief for migraine patients seeking an alternative to oral or intranasal routes.
$0.075BPart D
Peak9.4 years to LOEProduct is in peak lifecycle stage with 42 Part D claims in 2023, indicating established market presence but modest scale requiring focused commercial and medical teams.
Mechanism of Action
5-HT 1B/1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine headache through agonist effects at the 5-HT 1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (9)
An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)
Started May 2008
30 enrolled
Migraine Disorders
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)
Started Dec 2006
169 enrolled
Migraine Disorders
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)
Started Nov 2006
173 enrolled
Migraine Disorders
Study Of Sumatriptan Succinate Injection Kit In Patients With Migraine or Cluster Headache In Japan
Started Jun 2006
75 enrolled
Migraine Disorders
Bioequivalence Study of Sumatriptan Succinate Tablets 100 mg in Fed Conditions
Started Jul 2005
50 enrolled
Healthy
Worked on ZEMBRACE SYMTOUCH at Antares Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.